In summary, this real-world cohort study suggests that among patients with type 2 diabetes and bipolar disorder, SGLT-2 inhibitor therapy is associated with a lower risk of suicide-related events compared to DPP-4 inhibitor therapy. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.